Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022
Retrieved on:
Thursday, May 19, 2022
Primary hyperoxaluria, Șaeș, Infection, Trial of the century, AES, Webcast, ERA, Cohort, Conference, University, Concord, SEC, Immunoglobulin A, Immunoglobulin G, Extracellular matrix, Atrasentan, Therapy, LDHA, Downregulation and upregulation, COVID-19, Investor, RATS, RNA, Biomarker, Chemokine, University of Sydney, GLOBE, Inflammation, Hospital, Chronic kidney disease, IV, Concord Repatriation General Hospital, Fibrosis, Program, ETA, PD, Western literature, Population, Metabolism, Nasdaq, EDT, Injection site reaction, Nephrology, Immunoglobulin M, Kidney, Glomerulus (kidney), UPCR, Kidney disease, Industry, Forward-looking statement, Transcriptome, HIV disease progression rates, Vaccine, Pharmaceutical industry, Proteinuria, Safety, IgA nephropathy, MPGN, Pharmacokinetics, Chinook, Patient, Tolerability
Patients in Cohort 1 initially received an intravenous (IV) dose of 450 mg of BION-1301 every two weeks.
Key Points:
- Patients in Cohort 1 initially received an intravenous (IV) dose of 450 mg of BION-1301 every two weeks.
- As of the May 6, 2022 data cutoff, BION-1301 has been well-tolerated, with no serious adverse events or treatment discontinuations due to adverse events.
- BION-1301 durably reduced serum IgA and IgM levels, and to a lesser extent, IgG levels in all patients.
- Chinooks lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.